No Data
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics
Express News | Iteos Therapeutics Inc : JP Morgan Cuts Target Price to $22 From $24
ITeos Therapeutics | 10-Q: Q3 2024 Earnings Report
Gobinath OP :